The overexpression of HER2 is very common in DCIS, especially in tumours with unfavourable profiles and at a higher risk of recurrence, but the clinical significance is uncertain and it is not routinely evaluated [43,105,106,107]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.